EUVIMEDEUVIMED entdecken
Crossref

Posterior Reversible Encephalopathy Syndrome in Pediatric Hematopoietic Stem Cell Transplantation with Beta Major Thalassemia: The Association between the PRES Occurrence and Class of Beta Major Thalassemia

Leila Jafari, Maryam Behfar, Soroor Tabatabaie iD, Yalda Karamlou, Homa Kashani, Amir Reza Radmard, Rashin Mohseni, Parisa Naji, Fatemeh Ghanbari, Pooya Ashkevari, Hoda Fakhr, Shiva Mohammadi und 1 weitere

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2024. Verfasst von Leila Jafari und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Posterior Leukoencephalopathy Syndrome, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease, beta-Thalassemia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Allogeneic hematopoietic stem cell transplantation (HSCT) is the only definitive curative option for β‐major thalassemia patients (β‐MT). Posterior reversible encephalopathy syndrome (PRES) is a pervasive neurological complication which typically occurs following HSCT. β‐MT patients are prone to a higher PRES incidence due to long‐term immunosuppression; thus, it is imperative that these patients are closely monitored for PRES after HSCT. Patients and methods We included 148 pediatric patients with β‐MT who underwent HSCT between March 2015 and August 2022 in Children's Medical Center. Patients in this study were divided into two groups. The association between PRES and class of β‐MT and other risk factors were assessed and the overall survival rate was determined.

Results

Fourteen out of 112 patients (12%) with class I and II β‐MT developed PRES. However, PRES occurred in 11 out of 36 patients (30.5%) with β‐MT‐III. Our results indicated that there was a significant association between class III β‐MT and the occurrence of ( P = .004). Additionally, acute graft‐versus‐host disease (aGVHD) occurred in 80% and 44.7% of patients in the PRES and non‐PRES groups, respectively ( P = .001). The results of the Kaplan‐Meier analysis revealed that the 5‐year overall survival (OS) was 75.6% in the PRES group versus 95% in the non‐PRES group, which was statistically significant ( P = .001).

Conclusion

Based on our results, pediatric β‐MT III patients are at a higher risk of developing PRES. Additionally, pediatric β‐MT patients with a history of aGVHD, regardless of disease class, are more likely to develop PRES. Considering these results, PRES has a higher chance of being the etiology of symptoms and should be considered more often in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Posterior Leukoencephalopathy SyndromeHematopoietic Stem Cell TransplantationGraft vs Host Diseasebeta-ThalassemiaHumansChildRisk FactorsRetrospective Studies

Stichwörter der Autor:innen

hematopoietic stem cellpediatricsposterior reversible encephalopathy syndrome

Autor:innen und Institutionen

  • Pediatric Cell and Gene Therapy Research Centre, Gene, Cell & Tissue Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Research Methodology and Data Analysis, Institute for Environmental Research, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Radiology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Soroor Tabatabaie, Amir Ali Hamidieh

Zitieren

APA

Jafari, L., Behfar, M., Tabatabaie, S., Karamlou, Y., Kashani, H., Radmard, A. R., Mohseni, R., Naji, P., Ghanbari, F., Ashkevari, P., Fakhr, H., Mohammadi, S., & Hamidieh, A. A. (2024). Posterior Reversible Encephalopathy Syndrome in Pediatric Hematopoietic Stem Cell Transplantation with Beta Major Thalassemia: The Association between the PRES Occurrence and Class of Beta Major Thalassemia. Clinical Transplantation. https://doi.org/10.1111/ctr.15164

Vancouver

Jafari L, Behfar M, Tabatabaie S, Karamlou Y, Kashani H, Radmard AR, et al. Posterior Reversible Encephalopathy Syndrome in Pediatric Hematopoietic Stem Cell Transplantation with Beta Major Thalassemia: The Association between the PRES Occurrence and Class of Beta Major Thalassemia. Clinical Transplantation. 2024. doi:10.1111/ctr.15164

BibTeX
@article{Jafari2024,
  author = {Jafari, Leila and Behfar, Maryam and Tabatabaie, Soroor and Karamlou, Yalda and Kashani, Homa and Radmard, Amir Reza and Mohseni, Rashin and Naji, Parisa and Ghanbari, Fatemeh and Ashkevari, Pooya and Fakhr, Hoda and Mohammadi, Shiva and Hamidieh, Amir Ali},
  title = {Posterior Reversible Encephalopathy Syndrome in Pediatric Hematopoietic Stem Cell Transplantation with Beta Major Thalassemia: The Association between the PRES Occurrence and Class of Beta Major Thalassemia},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15164}
}
Kostenlos starten →